Immunotherapy for Prostate Cancer

Immunotherapy for Breast Cancer: Hot Molecules

Immunotherapy for Prostate Cancer: Review

Immunotherapy for prostate cancer: prostate cancer vaccines
1, Autologous vaccines: Sipuleucel-T is an autologous vaccine in which the patient's own peripheral blood mononuclear cells, along with APCs, are retrieved via leukapheresis. The cells are then activated with a recombinant fusion protein consisting of PAP linked to granulocyte-macrophage colony stimulating factor (GM-CSF), an immune cell activator.
2, Cell-based vaccines: GVAX is an allogenic cell-based prostate cancer vaccine that is composed of both hormone-sensitive and -naïve prostate cancer cell lines that have been genetically modified to bear GM-CSF. GM-CSF results in recruitment of DCs, which
then present antigens to T-cells invoking an anti-tumour cascade of immune responses. The whole tumour cell is used as the antigen, rather than just the PAP, as in sipuleucel- T, facilitating both humoural and cellular immune responses.
3, DNA-based vaccines: DNA-based vaccines consist of bacterial plasmids constructed to contain the coding sequence of a targeted antigen, which can be taken up by cells. These transformed cells express genes that can induce an immune response.
Bacterial plasmids are attractive in their simplicity, stability, and cost-effectiveness, which can be encoded with adjuvants and cytokines to increase their immune response. Phase I trials have been done targeting various TAAs, including PSA, PSMA, PAP, and the cancer-testis antigen NY-ESO-1.
4, Viral-based vaccines: Prostvac-VF is a vaccine comprised of two recombinant viral vectors that each encode for PSA and three immune costimulatory molecules including: co-stimulatory molecule for T cells (B7-1); intracellular adhesion molecule 1, and lymphocyte function-associated antigen 3. The vaccinia virus-based vector is used for priming and is followed by fowl pox virus-based vector boosts. This helps to overcome the host anti-vector antibody responses to the original vector. GM-CSF is co-administered to further boost immune response. The virus infects APCs, promoting cell surface protein expression and interaction with T-cells that facilitate a targeted immune response and cell-mediated tumour cell destruction. Current trials are testing Prostvac-VF in men with castration-resistant disease, as well as in combination with other traditional therapies and immunotherapies.
Immunotherapy for prostate cancer: immune checkpoint blockade
Immune responses are kept in balance by immune checkpoints that oppose co-stimulatory pathways, as well as clonal selection, activation, proliferation, trafficking, and effector function. Under normal conditions, these mechanisms help maintain self-tolerance, duration, and strength of immune responses, and aim to minimize damage to surrounding self-tissues. Alteration of these pathways in tumour cells re-directs T cell-mediated immunity such that checkpoint regulating molecules altered within the tumour or surrounding immune cells send a negative signal into the binding T cell, thus leading to its exhaustion. Recent successful immunotherapies have extensively exploited these mechanisms to enhance immune-mediated tumour cell destruction. The most representative ones are CTLA-4 based immunotherapy and PDL-1/PD-1 axis-based immunotherapy.
CTLA-4 is a co-inhibitory signal that binds B7 with greater affinity. CTLA-4 blockade removes the inhibition and results in T cell activation against tumour cells. Ipilimumab is a human monoclonal antibody against CTLA-4, first approved for metastatic melanoma in 2011. Several current trials are testing ipilimumab in patients with prostate cancer as a monotherapy and in combination settings. To date, monotherapy with ipilimumab in a phase III trial assessing men with castration-resistant disease was negative overall; however, there has been demonstration of good biochemical response and there was a signal of a survival benefit in subgroups of patients with favourable prognostic features.
Programmed cell death (PD) 1 is a cell surface molecule on T-cells that interacts with ligands, including PD-L1. This interaction inhibits downstream T cell receptor signalling, preventing T cell activation leading to their exhaustion and subsequent apoptosis. PD-L1 is expressed on a variety of cells, such as T, epithelial, endothelial, and tumour cells after exposure to IFN-γ. This interaction helps to regulate the immune response by reducing autoimmunity and developing self-tolerance. Similar to CTLA-4 targeting by ipilimumab, PD-1 is an additional but non-redundant pathway for which inhibition results in a targeted anti-tumour
response. Currently, the PD-1 based antibody, pembrolizumab is being investigated in a phase II trial in metastatic castration-resistant prostate cancer (CRPC) after androgen-deprivation therapy (ADT) (NCT02312557). Pidlizumab is another PD-1 monoclonal antibody currently being investigated in metastatic CRPC in combination with Sipuleucel-T and cyclophosphamide (NCT01420965).

Immunotherapy for Prostate Cancer: Reference

Ren R et al. A primer on tumour immunology and prostate cancer immunotherapy[J]. Canadian Urological Association Journal, 2016, 10(1-2): 60-5.
Saad F et al. Current and emerging immunotherapies for castration-resistant prostate cancer. Urology 2015;85:976-86.

What is Immunotherapy
Cancer Immunotherapy
What is Immunotherapy for Cancer
Monoclonal Antibody for Cancer Immunotherapy
Immune Checkpoint
Vaccines for Cancer Immunotherapy
Immune Modulation for Cancer Immunotherapy
Oncolytic Viruses for Cancer Immunotherapy
Adoptive Immunotherapy for Cancer+
- What is Adoptive Immunotherapy for Cancer
- Tumor-Infiltrating Lymphocytes (TILs) for Cancer Immunotherapy
- Chimeric Antigen Receptor (CAR) T-cell for Cancer Immunotherapy
- Epstein–Barr Virus (EBV)-Specific T Cells for Cancer Immunotherapy
Immunotherapy for Lung Cancer
Immunotherapy for Melanoma
Cancer Immunotherapy for Breast Cancer
Immunotherapy for Prostate Cancer
Immunotherapy for Pancreatic Cancer
Immunotherapy for Ovavian Cancer
Immunotherapy for Colon Cancer
Immunotherapy for Bladder Cancer
Immunotherapy for Liver Cancer
Immunotherapy for Kidney Cancer
Immunotherapy for Brain Cancer
Immunotherapy for Esophageal Cancer
Immunotherapy for Gastric Cancer
Cancer Immunotherapy for Leukemia
Cancer Immunotherapy Clinical Trials
Cancer Immunotherapy Companies
Immunotherapy Drugs for Cancer
Breakthrough of Cancer Immunotherapy
Side Effects of Immunotherapy for Cancer
Cancer Immuotherapy Conference
Cancer Immuotherapy Related Molecules+
- Immune Checkpoint Targets
- Monoclonal Antibody Targets for Cancer Immunotherapy
- Vaccine Antigens for Cancer Immunotherapy
- Cytokines for Cancer Immunotherapy
- Tumor Antigens for Cancer Immunotherapy
Allergy Immunotherapy
Autoimmune Diseases Immunotherapy
Immunotherapy Related Molecules
Sublingual Immunotherapy
Side Effects of Immunotherapy
Immunotherapy Drugs
Adoptive Immunotherapy
Journal of Immunotherapy
Immunotherapy Conference